Literature DB >> 11562951

Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.

M D Miller1, N A Margot, K Hertogs, B Larder, V Miller.   

Abstract

The presence of the lamivudine-associated M184V RT mutation increases tenofovir susceptibility in multiple HIV genotypes. Tenofovir is uniquely active against multinucleoside-resistant HIV expressing the Q151M mutation, but shows reduced susceptibility to the T69S insertion mutations. HIV with common forms of zidovudine and lamivudine resistance are susceptible to tenofovir, corroborating phase II clinical results demonstrating the activity of tenofovir DF in treatment-experienced patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11562951     DOI: 10.1081/NCN-100002483

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  24 in total

1.  Uncommon association of T69 3-base-pair insertion plus Q151M multidrug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Catherine Tamalet; Mireille Henry; Philippe Colson; Nouara Yahi; Cecile Poggi; Alain Lafeuillade
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 2.  Antiretroviral therapy : optimal sequencing of therapy to avoid resistance.

Authors:  Jorge L Martinez-Cajas; Mark A Wainberg
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

Authors:  Zhufang Li; Brian Terry; William Olds; Tricia Protack; Carol Deminie; Beatrice Minassian; Beata Nowicka-Sans; Yongnian Sun; Ira Dicker; Carey Hwang; Max Lataillade; George J Hanna; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

4.  Drug resistance mutation profile and accumulation kinetics in human immunodeficiency virus-positive individuals infected with subtypes B and F failing highly active antiretroviral therapy are influenced by different viral codon usage patterns.

Authors:  A Waléria-Aleixo; A N Martins; M B Arruda; R M Brindeiro; R M Da-Silva; F F Nobre; D B Greco; A Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

5.  Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity.

Authors:  Diane N Singhroy; Mark A Wainberg; Thibault Mesplède
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

Review 6.  Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.

Authors:  Katherine A Lyseng-Williamson; Neil A Reynolds; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Lack of viral control and development of combination antiretroviral therapy escape mutations in macaques after bone marrow transplantation.

Authors:  Christopher W Peterson; Kevin G Haworth; Patricia Polacino; Meei-Li Huang; Craig Sykes; Willimark M Obenza; Andrea C Repetto; Angela Kashuba; Roger Bumgarner; Stephen C DeRosa; Ann E Woolfrey; Keith R Jerome; James I Mullins; Shiu-Lok Hu; Hans-Peter Kiem
Journal:  AIDS       Date:  2015-08-24       Impact factor: 4.177

8.  MALDI Mass Spectrometry Imaging Reveals Heterogeneous Distribution of Tenofovir and Tenofovir Diphosphate in Colorectal Tissue of Subjects Receiving a Tenofovir-Containing Enema.

Authors:  Herana Kamal Seneviratne; Craig W Hendrix; Edward J Fuchs; Namandjé N Bumpus
Journal:  J Pharmacol Exp Ther       Date:  2018-07-23       Impact factor: 4.030

Review 9.  Advancement of structure-activity relationship of multidrug resistance-associated protein 2 interactions.

Authors:  Li Xing; Yiding Hu; Yurong Lai
Journal:  AAPS J       Date:  2009-06-03       Impact factor: 4.009

10.  Tenofovir resistance and resensitization.

Authors:  Katharina Wolf; Hauke Walter; Niko Beerenwinkel; Wilco Keulen; Rolf Kaiser; Daniel Hoffmann; Thomas Lengauer; Joachim Selbig; Anne-Mieke Vandamme; Klaus Korn; Barbara Schmidt
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.